Design Therapeutics, Inc. (DSGN) Tops Q4 EPS by 6c

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q4 EPS of ($0.27), $0.06 better than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Synchrony partners with OpenAI to integrate AI into shopping
• Cohen & Steers and DLC acquire Virginia grocery shopping center